Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study
Canadian Journal of Ophthalmology · 2026-08 · 61 (4) · 990-998
DOI: 10.1016/j.jcjo.2026.02.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Ophthalmology, 2026-08. Verfasst von Sara Kamali Zonouzi und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Pharmacovigilance, Eye Diseases. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Roche.
Themen: Patientensicherheit
Abstract (Originalsprache)
OBJECTIVE To evaluate the postmarketing ocular adverse events (AEs) reported for intravitreal antivascular endothelial growth factor (anti-VEGF) therapies, aflibercept (2 mg and 8 mg), and faricimab (6 mg). DESIGN Retrospective pharmacovigilance analysis. PARTICIPANTS Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS We conducted a retrospective pharmacovigilance analysis of the FAERS database from the fourth quarter of 2023 to the first quarter of 2025. Descriptive statistics and reporting odds ratio (ROR) analysis were employed to evaluate and compare AEs between 2 mg aflibercept, 8 mg aflibercept, and faricimab. RESULTS A total of 462 unique reports of AEs secondary to 2 mg aflibercept, 151 reports for 8 mg aflibercept, and 2 427 reports for faricimab were identified. Ocular AEs that were disproportionately over-reported for all of the 3 agents included intraocular injection complications, increased intraocular pressure, endophthalmitis, reduced visual acuity, eye inflammation, uveitis, visual impairment, and blurred vision. CONCLUSIONS In this study, faricimab generally showed lower point estimates for ROR of ocular AEs compared to 2 mg and 8 mg aflibercept; however, the wider confidence intervals for some outcomes reflect the limited number of reports and highlight the need for continued safety monitoring, particularly given the inherent reporting biases and lack of detailed patient or dosing information in the FAERS database.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON.
- Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON; Mississauga Retina Institute, Mississauga, ON; School of Medicine, Toronto Metropolitan University, Toronto, ON. Electronic address: P…
Förderung
- Roche
Zitieren
APA
Zonouzi, S. K., Balas, M., & Arjmand, P. (2026). Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study. Canadian Journal of Ophthalmology, 61(4), 990-998. https://doi.org/10.1016/j.jcjo.2026.02.010
Vancouver
Zonouzi SK, Balas M, Arjmand P. Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study. Canadian Journal of Ophthalmology. 2026;61(4):990-998. doi:10.1016/j.jcjo.2026.02.010
BibTeX
@article{Zonouzi2026,
author = {Zonouzi, Sara Kamali and Balas, Michael and Arjmand, Parnian},
title = {Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study},
journal = {Canadian Journal of Ophthalmology},
year = {2026},
volume = {61},
number = {4},
pages = {990--998},
doi = {10.1016/j.jcjo.2026.02.010}
}
EUVIMED